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Murray A. Freedman, MS, MD, FACOG,4 and Sharon J. Parish, MD, NCMP, IF5On August 18, 2015, the U.S. Food and Drug Administration
(FDA) approved a ﬁrst in class multifunctional serotonin agonist
and antagonist medication, ﬂibanserin, for the treatment of
generalized acquired hypoactive sexual desire disorder (HSDD)
in premenopausal women. This approval was surrounded by
political posturing that has resulted in naysayers attacking the
science based on their feelings rather than the facts. Although the
FDA was criticized for gender bias—after all, they had fast-
tracked sildenaﬁl for men with erectile dysfunction within 6
months with fewer than 2,000 subjects, whereas ﬂibanserin for
women with HSDD was repeatedly required to perform addi-
tional clinical trials and ﬁled with approximately 11,000 sub-
jects—whether there was actual gender bias in the FDA is no
longer relevant. What is relevant is that science requires that the
facts speak for themselves.
In what might be an unprecedented action, Hylton Joffe, in
his role as director of the Division of Bone Reproductive and
Urologic Products at the FDA, and his colleagues in this division,
defended their decision of ﬂibanserin as having a positive risk-
beneﬁt ratio.1 However, their commentary reinforced and
perpetuated some of the agency’s concerns (their feelings) sur-
rounding the ﬂibanserin approval.
The International Society for the Study of Women’s Sexual
Health (ISSWSH)2 is the pre-eminent international organization
dedicated to the science of sexual medicine in women and ed-
ucation in women’s sexual health. The Executive Committee of
ISSWSH applauds the publication of the article by Joffe et al1 in
the New England Journal of Medicine that summarizes the his-
toric development program of ﬂibanserin and their ﬁrst-everReceived March 5, 2016. Accepted March 15, 2016.
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Unfortunately, Joffe et al mischaracterized the beneﬁts of ﬂi-
banserin as “small” (Table 1 in Joffe et al1) and overemphasized
the risks of ﬂibanserin. We believe that emphasizing the facts
would be helpful for those health care practitioners who are
uncertain as to beneﬁt of ﬂibanserin for their premenopausal
patients with bothersome low sexual interest.1
The FDA’s analyses underestimate the clinical meaningfulness
for biopsychosocial conditions such as HSDD. With HSDD, the
clinical beneﬁts get “watered down” by non-responders, placebo
response, and high levels of baseline “duty” sex.3 Responder
analyses (conspicuously absent1) clarify the actual beneﬁts of this
medical therapy. Responders, deﬁned by self-report on the Pa-
tient Global Impression of Improvement, show a return to near
normal premenopausal frequencies of sexual activity4 in 8 weeks,
despite HSDD of 4.5 years’ duration (mean) in these trials.
Responders also show signiﬁcant improvement in desire scores
on the Female Sexual Function Index and decreases in sexually
related distress on the Female Sexual Distress Scale, and these are
validated instruments.
The FDA’s overemphasis on the “major safety concerns” of
ﬂibanserin, citing “hypotension, and syncope,” which are rare to
infrequent events5 when ﬂibanserin is taken properly at bedtime,
also is excessive. Labeling prohibiting concomitant alcohol use is
unwarranted, because this recommendation was based on an
extreme alcohol challenge study in which subjects rapidly (within
10 minutes) consumed the equivalent of two to four “alcoholic
drinks” in the morning with ﬂibanserin or placebo. It had
been known since early in the phase 2 dosing regimen trials
(circa 2006e2007) that ﬂibanserin should be dosed at bedtime
(not in the morning) because of its sedating side effects. The
three pivotal North American phase 3 trials in which ﬂibanserin
was dosed at bedtime and alcohol was not restricted demon-
strated that, among the 58% of participants who admitted to
“social drinking,” the overall rate of syncope and pre-syncope was
0.5% in the ﬂibanserin group and 0.3% in the placebo group.6,7
These rates of syncope and pre-syncope are similar to existing
FDA-approved active central nervous system agents. For
example, the package insert data for bupropion show that the
placebo-corrected rate for hypotension is 0.3% and that for
syncope is 0.7%.8 The package insert data for paroxetine show
that the placebo-corrected rate for postural hypotension is
0.7%.9 It should be emphasized that ﬂibanserin requires a Risk
Evaluation and Mitigation Strategy program, unlike bupropione69
e70 Simon et aland paroxetine. In addition, the reassuring results of the next-day
driving study demonstrated the statistically signiﬁcant beneﬁts of
ﬂibanserin on cognitive function and driving performance10 that
are conspicuously absent from the commentary by Joffe et al.1
Joffe et al’s Table 2 supposedly illustrates the absence of sexual
bias in the FDA’s drug approval processes. However, including
vulvovaginal atrophy therapies in Table 2 and excluding more
than 12 branded male testosterone products and countless male
testosterone generic products is misleading. Vulvovaginal atrophy
or dyspareunia, now referred to as genitourinary syndrome of
menopause,11 results from hypogonadism but is erroneously
classiﬁed as a sexual dysfunction, as if it, too, were a bio-
psychosocial phenomenon like HSDD. Genitourinary syndrome
of menopause is an estrogen deﬁciency syndrome very effectively
treated with estrogenic therapies locally and systemically and
often adequately ameliorated with over-the-counter lubricants
and moisturizers.
What is clearly relevant and simultaneously misleading is Joffe
et al’s misrepresentation of sexual equality in drug approvals. For
example, men’s testosterone therapies are FDA “approved only
for replacement (hypogonadism) . not for . sexual dysfunc-
tion,” implying menopausal women don’t suffer symptomatic
hypogonadism or androgen insufﬁciency syndrome.12 Male
testosterone product approval requires efﬁcacy studies judged
solely by restoration of normal testosterone concentrations and
short-term safety trials (typically 6 months). In contrast, female
testosterone trials necessitate HSDD treatment efﬁcacy, the
requisite restoration of normal testosterone concentrations, and
long-term safety studies of 5 years’ duration.13 This difference is
the true double-standard sexual bias.
The feelings of the Executive Committee of ISSWSH are
based on science and the facts deserve to speak for themselves;
therefore, this report is being published in an ofﬁcial publication
of the ISSWSH to give the reader the opportunity to make a
decision about this ﬁrst in class drug based on the facts.
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